FY2025 · ended Dec 31, 2025 · Revenue $606.88M, -14.9% YoY · Filed Feb 26, 2026
OPKO Health, Inc. (OPK) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $606.9 million and a net loss of $225.7 million. Free cash flow was -$190.8 million. As of Sep 30, 2026 it held $428.5 million in cash and investments and $515.6 million in total debt.
Revenue (TTM)
$654.10M
+90.8% vs year-ago TTM
Net income (TTM)
$-148.06M
+17.9% vs year-ago TTM
Operating cash flow (TTM)
$-125.05M
Free cash flow (TTM)
$-135.34M
EPS (TTM)
$-0.20
Dividend per share
None
Shares outstanding
759.07M
+13.0% vs prior year
Net cash
$-87.11M
as of Sep 30, 2026
Operating margin
-12.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OPK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- Accelerated filer
- SEC CIK
- 944809
- Former names
- EXEGENICS INC (until Jun 13, 2007); eXegenics Inc (until Jun 13, 2007); CYTOCLONAL PHARMACEUTICS INC /DE (until Jun 4, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $606.9M | $713.1M | $863.5M | $1.0B | $1.8B |
| Operating income | -$117.4M | -$152.1M | -$157.0M | -$226.3M | $18.8M |
| Net income | -$225.7M | -$53.2M | -$188.9M | -$328.4M | -$30.1M |
| Diluted EPS | -$0.30 | — | — | -$0.46 | -$0.05 |
| Operating cash flow | -$178.5M | -$183.5M | -$28.2M | -$95.2M | $38.3M |
| Free cash flow | -$190.8M | -$208.5M | -$44.5M | -$119.8M | $6.2M |
| Total assets | $1.9B | $2.2B | $2.0B | $2.2B | $2.4B |
| Total liabilities | $664.0M | $834.8M | $622.5M | $605.6M | $714.6M |
| Stockholders' equity | $1.3B | $1.4B | $1.4B | — | $1.7B |
| Cash and investments | $378.6M | $481.2M | $112.0M | $181.3M | $145.4M |
| Total debt | $399.0M | $507.4M | $87.0M | $305.7M | $265.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Sep 30, 2026 |
| 10-Q/A | Amended quarterly report | Aug 28, 2026 | Jun 30, 2026 |
| 10-Q/A | Amended quarterly report | Aug 28, 2026 | Mar 31, 2026 |
All 1000 OPKO Health, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.